Amanat, F., and Krammer, F. (2020). SARS-CoV-2 Vaccines: Status Report. Immunity 52(4), 583-589. doi: 10.1016/j.immuni.2020.03.007.
Bajaj, V., Gadi, N., Spihlman, A.P., Wu, S.C., Choi, C.H., and Moulton, V.R. (2020). Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? Front Physiol 11, 571416. doi: 10.3389/fphys.2020.571416.
Balz, K., Trassl, L., Hartel, V., Nelson, P.P., and Skevaki, C. (2020). Virus-Induced T Cell-Mediated Heterologous Immunity and Vaccine Development. Front Immunol 11, 513. doi: 10.3389/fimmu.2020.00513.
Braciale, T.J., and Hahn, Y.S. (2013). Immunity to viruses. Immunol Rev 255(1), 5-12. doi: 10.1111/imr.12109.
Cai, C., Ahmed, O.A., Shen, H., and Zeng, S. (2020). Which cancer type has the highest risk of COVID-19 infection? J Infect. doi: 10.1016/j.jinf.2020.05.028.
Cao, X. (2020). COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 20(5), 269-270. doi: 10.1038/s41577-020-0308-3.
Cohen, J.F., Korevaar, D.A., Matczak, S., Chalumeau, M., Allali, S., and Toubiana, J. (2020). COVID-19-Related Fatalities and Intensive-Care-Unit Admissions by Age Groups in Europe: A Meta-Analysis. Front Med (Lausanne) 7, 560685. doi: 10.3389/fmed.2020.560685.
Currier, J.R., Kuta, E.G., Turk, E., Earhart, L.B., Loomis-Price, L., Janetzki, S., et al. (2002). A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260(1-2), 157-172. doi: 10.1016/s0022-1759(01)00535-x.
DiPiazza, A., Richards, K.A., Knowlden, Z.A., Nayak, J.L., and Sant, A.J. (2016). The Role of CD4 T Cell Memory in Generating Protective Immunity to Novel and Potentially Pandemic Strains of Influenza. Front Immunol 7, 10. doi: 10.3389/fimmu.2016.00010.
Dyer, O. (2020). Covid-19: Black people and other minorities are hardest hit in US. BMJ 369, m1483. doi: 10.1136/bmj.m1483.
Giwa, A.L., Desai, A., and Duca, A. (2020). Novel 2019 coronavirus SARS-CoV-2 (COVID-19): an overview for emergency clinicians. Pediatr Emerg Med Pract 17(5), 1-24.
Grifoni, A., Weiskopf, K., Ramirez, S., I., Mateus, J., Dan, J., M., Moderbacher, C., R., et al. (2020). Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell In Press, Journal Pre-proof. doi: 10.1016/j.cell.2020.05.015.
Hotez, P.J., Corry, D.B., and Bottazzi, M.E. (2020). COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol. doi: 10.1038/s41577-020-0323-4.
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223), 497-506. doi: 10.1016/S0140-6736(20)30183-5.
Chen, J., Qi, T., Liu, L., Ling, Y., Qian, Z., Li, T., et al. (2020). Clinical progression of patients with COVID-19 in Shanghai, China. J Infect 80(5), e1-e6. doi: 10.1016/j.jinf.2020.03.004.
Chen, Y., Klein, S.L., Garibaldi, B.T., Li, H., Wu, C., Osevala, N.M., et al. (2021). Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Res Rev 65, 101205. doi: 10.1016/j.arr.2020.101205.
Iwasaki, A., and Yang, Y. (2020). The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol. doi: 10.1038/s41577-020-0321-6.
Jin, J.M., Bai, P., He, W., Wu, F., Liu, X.F., Han, D.M., et al. (2020). Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health 8, 152. doi: 10.3389/fpubh.2020.00152.
Kang, S.M., and Compans, R.W. (2009). Host responses from innate to adaptive immunity after vaccination: molecular and cellular events. Mol Cells 27(1), 5-14. doi: 10.1007/s10059-009-0015-1.
Li, Z., Tomlinson, A.C., Wong, A.H., Zhou, D., Desforges, M., Talbot, P.J., et al. (2019). The human coronavirus HCoV-229E S-protein structure and receptor binding. Elife 8. doi: 10.7554/eLife.51230.
Mehta, V., Goel, S., Kabarriti, R., Cole, D., Goldfinger, M., Acuna-Villaorduna, A., et al. (2020). Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. doi: 10.1158/2159-8290.CD-20-0516.
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., et al. (2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11(1), 1620. doi: 10.1038/s41467-020-15562-9.
Paces, J., Strizova, Z., Smrz, D., and Cerny, J. (2020). COVID-19 and the immune system. Physiol Res.
Podrazil, M., Horvath, R., Becht, E., Rozkova, D., Bilkova, P., Sochorova, K., et al. (2015). Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget 6(20), 18192-18205. doi: 10.18632/oncotarget.4145.
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., et al. (2020). Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. doi: 10.1093/cid/ciaa248.
Reber, A.J., Music, N., Kim, J.H., Gansebom, S., Chen, J., and York, I. (2018). Extensive T cell cross-reactivity between diverse seasonal influenza strains in the ferret model. Sci Rep 8(1), 6112. doi: 10.1038/s41598-018-24394-z.
Ricke, D. (2020). Ricke, Darrell and Malone, Robert W., Medical Countermeasures Analysis of 2019-nCoV and Vaccine Risks for Antibody-Dependent Enhancement (ADE) (2/27/2020). Available at SSRN: https://ssrn.com/abstract=3546070 or http://dx.doi.org/10.2139/ssrn.3546070
Saletti, G., Gerlach, T., Jansen, J.M., Molle, A., Elbahesh, H., Ludlow, M., et al. (2020). Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. Sci Rep 10(1), 21447. doi: 10.1038/s41598-020-78506-9.
Sama, I.E., Ravera, A., Santema, B.T., van Goor, H., Ter Maaten, J.M., Cleland, J.G.F., et al. (2020). Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J 41(19), 1810-1817. doi: 10.1093/eurheartj/ehaa373.
Siegel, R.L., Miller, K.D., and Jemal, A. (2019). Cancer statistics, 2019. CA Cancer J Clin 69(1), 7-34. doi: 10.3322/caac.21551.
Stakheev, D., Taborska, P., Strizova, Z., Podrazil, M., Bartunkova, J., and Smrz, D. (2019). The WNT/beta-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro. Sci Rep 9(1), 4761. doi: 10.1038/s41598-019-41182-5.
Subramaniam, K.S., Lant, S., Goodwin, L., Grifoni, A., Weiskopf, D., and Turtle, L. (2020). Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design. Front Immunol 11, 517. doi: 10.3389/fimmu.2020.00517.
Taborska, P., Bartunkova, J., and Smrz, D. (2018). Simultaneous in vitro generation of human CD34(+)-derived dendritic cells and mast cells from non-mobilized peripheral blood mononuclear cells. J Immunol Methods 458, 63-73. doi: 10.1016/j.jim.2018.04.005.
Taborska, P., Stakheev, D., Strizova, Z., Vavrova, K., Podrazil, M., Bartunkova, J., et al. (2017). Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients. Med Oncol 34(10), 173. doi: 10.1007/s12032-017-1035-x.
Tetro, J.A. (2020). Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect 22(2), 72-73. doi: 10.1016/j.micinf.2020.02.006.
Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., and Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181(2), 281-292 e286. doi: 10.1016/j.cell.2020.02.058.
Wu, S.Q., Su, H., Wang, Y.H., and Zhao, X.K. (2019). Role of tumor-associated immune cells in prostate cancer: angel or devil? Asian J Androl 21(5), 433-437. doi: 10.4103/aja.aja_47_19.
Zhang, L., Zhu, F., Xie, L., Wang, C., Wang, J., Chen, R., et al. (2020). Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. doi: 10.1016/j.annonc.2020.03.296.
Zou, L., Dai, L., Zhang, Y., Fu, W., Gao, Y., Zhang, Z., et al. (2020). Clinical Characteristics and Risk Factors for Disease Severity and Death in Patients With Coronavirus Disease 2019 in Wuhan, China. Front Med (Lausanne) 7, 532. doi: 10.3389/fmed.2020.00532.